Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn’s Disease

ABSTRACT: A Phase 2b study to evaluate the efficacy and safety of brazikumab (MEDI2070) in participants with moderate to severe Crohn’s disease who have failed or are intolerant to anti-tumor necrosis factor-alpha (anti-TNFα) therapy.

DISEASE(S): Crohn's Disease,Crohn Disease

PROVIDER: 2200013 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR